Vevo 2100 Imaging System - High Resolution Ultrasound for Biomicroscopy

描述（由申请人提供）：在过去10年中，对小鼠和大鼠的高分辨率非侵入性成像的需求大幅增加，特别是在心血管和心肺领域。转基因动物模型的出现和对评估外周血管系统、体内干细胞和基因治疗以及致瘤性生长的兴趣导致了该仪器的多种用途的激增。对于学术机构来说，提供最先进的超声设备是至关重要的，该设备提供了足以评估啮齿动物模型中的心血管功能、血流和外周循环的广泛的时间和空间分辨率。该提案要求为最先进的高分辨率超声生物显微镜设备提供资金：Visual Sonics Vevo 2100。该仪器将由伊利诺伊大学芝加哥分校（UIC）的研究资源中心管理和操作。该中心的使命是让广大的新老调查人员能够使用通常成本高昂的仪器。该仪器对现有和新招募的研究者的好处是（1）能够在肌肉和肿瘤中进行血流定量，并测量肥大和适应不良心脏中的主动脉和肺动脉返流，（2）以更高的帧速率和更高的分辨率采集数据，同时将这些数据选通到电生理事件，以及（3）准确地测量心肌的用户定义区域中的肌肉收缩异常或肌肉收缩的变化。本申请中列出的所有研究者至少有一个目前资助的R01。此外，三名研究人员是最近更新的计划项目赠款的一部分。其中三位主要研究者也有多个合作出版物。需要使用这一工具的研究项目大致可分为：（1）与肥大性和扩张性心肌病相关的不适应性翻译后修饰和突变，（2）基于遗传和干细胞的方法来拯救心脏免于由心肌梗死、高血压和肌节蛋白突变引起的衰竭，（3）肺血管和右心功能，和（4）肌营养不良，（5）与骨骼肌外周缺血相关的氧化应激。

DESCRIPTION (provided by applicant): The need for high resolution non-invasive imaging for mice and rats has seen an enormous increase in the last 10 years, particularly in the cardiovascular and cardiopulmonary field. The advent of transgenic animal models and the interest in assessing the peripheral vasculature, stem cell and gene therapy in vivo, and tumorigenic growth has led to a surge in multiple uses for this instrumentation. It is paramount for an academic institution to provide state-of-the-art ultrasound equipment that offers a wide range of temporal and spatial resolution sufficient for assessing cardiovascular function, blood flow, and peripheral circulation in the rodent model. This proposal requests funding for a state-of-the-art high resolution ultrasound bio microscopy device: the Visual Sonics Vevo 2100. The instrument will be managed and operated by the Research Resources Center at the University of Illinois at Chicago (UIC). The Center's mission is to allow a broad base of new and established investigators access to instrumentation that would ordinarily be cost-prohibitive. The benefits of this instrument to existing and newly recruited investigators are (1) the ability to perform blood flow quantification in muscle and tumors, and measure aortic and pulmonary artery regurgitation in hypertrophic and maladaptive hearts, (2) acquire data at higher frame rates and higher resolution while gating these data to electrophysiological events and (3) accurately measure muscle contractile abnormalities or changes in muscle contraction in a user-defined region of the myocardium. All investigators listed on this application have at least one currently funded R01. In addition, three investigators are part of a recently renewed Program Project Grant. Three of the major investigators also have multiple collaborative publications. Research projects requiring the use of this instrument can be broadly classified as: (1) maladaptive post-translational modifications and mutations linked to hypertrophic and dilated cardiomyopathies, (2) genetic and stem cell based approaches to rescue hearts from failure imposed by myocardial infarction, hypertension and mutations of sarcomeric proteins, (3) pulmonary vascular and right heart function, and (4) muscular dystrophy, and (5) oxidative stress associated with peripheral ischemia in skeletal muscle.